FGFR1 and neuroendocrine carcinoma: FGFR1 SVs/REs demonstrated the greatest frequency in glioma (SVs: 239/11 150, 2.1%; REs: 68/11 150, 0.6%), salivary gland cancer (SVs: 6/1495, 0.4%; REs: 25/1495, 1.7%), and female-neuroendocrine cancers (SVs: 3/362, 0.8%; REs: 2/362, 0.6%; Figure 2A).